Product
TriPRIL CAR T Cells
1 clinical trial
2 indications
Indication
Multiple MyelomaIndication
Multiple Myeloma in RelapseClinical trial
A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-01-01